Send me real-time posts from this site at my email

Why Agenus Stock Sank on Tuesday

What happened

Even on a generally downbeat day for the stock market, Agenus (NASDAQ: AGEN) was quite a downer on Tuesday. The biotech company's shares fell by just over 6% on the day because of a notable C-suite departure.

So what

Agenus announced in a tersely worded regulatory filing that chief legal and compliance officer Adam Krauss has served notice that he will be vacating his position, effective this Friday, July 30.

Image source: Getty Images.

The company did not provide a reason or reasons for his move. It also did not divulge any plans to find a replacement for the outgoing executive.

Krauss was not a longtime Agenus employee. According to his LinkedIn page, he began his tenure at the company last November. Prior to that, he served for over four years as chief legal counsel at two different units of healthcare device maker Medtronic. This followed a nearly 10-year stint in several top legal positions at Covidien, which was acquired by Medtronic in 2015.

Now what

The seemingly abrupt exit by a top legal executive threatens to dampen the company's good momentum Agenus was enjoying its stock performance and its growing reputation among investors. This began in mid-May, when the cancer drug developer signed a potentially $1.36 billion deal to license its antibody program AGEN1777 to pharmaceutical industry giant Bristol Myers Squibb.

While Krauss' departure isn't necessarily a deal-breaker for Agenus, its apparent suddenness is concerning, as is the company's tight-lipped disclosure on the matter. Hopefully it's not indicative of deeper issues at this promising company.

10 stocks we like better than Agenus
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Agenus wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue